FGF2 suppresses E-cadherin expression via the PI3K/Akt and MAPK/ERK signaling pathways.

<p>(A) SKOV-3 cells were treated with 10 ng/ml FGF2 for 0 to 120 min as indicated. Phosphorylated and total Akt, phosphorylated and total ERK, and β-actin levels were analyzed by Western blot analysis. (B) OVCAR-4 and SKOV-3 cells were pretreated with wortmannin (1 µM) or U0126 (10 µM) for 30 min before the addition of FGF2 (10 ng/ml) for 30 min. Phosphorylated and total Akt, phosphorylated and total ERK protein levels were analyzed by Western blotting. The β-actin antibody was used as a control for equal loading. (C) OVCAR-4 and SKOV-3 cells were pretreated with wortmannin (1 µM) or U0126 (10 µM) alone or in the presence of 10 ng/ml FGF2 for 24 h, after which E-cadherin protein levels were analyzed by Western blotting. Results represent the mean ± SEM [(A) & (B) n = 3; (C) n = 6; values without a common letter are significantly different, <i>P</i><0.05]. Data were analyzed by one-way ANOVA followed by Tukey's multiple comparison test.